SV Health Investors (SV) announces the appointment of Alex Badamchi-Zadeh PhD, strengthening their transatlantic Biotech team

in SV News

  • Alex joins from SV portfolio company Xilio Therapeutics where he led Business Development and Strategy
  • Strengthens the SV Biotech team as their first biotech focused fund, SV7 Impact Medicine Fund (IMF) closed at $265m

Boston, MA & London, UK (September 07, 2020) – SV, a leading transatlantic venture capital and growth equity firm, today announces the appointment of Alex Badamchi-Zadeh PhD, as Senior Associate.

This appointment grows the Biotech Investment team and Alex brings valuable experience to the team. As a Senior Associate in the biotechnology investment team, Alex will contribute to creating and the finance structuring of companies developing impactful medicines.

Alex will be particularly focused on the investments made through the SV7 IMF, SV’s first fund focused solely on biotechnology. The SV7 IMF mission is to turn scientific breakthroughs into successful biotech companies producing high impact precision medicine drugs for poorly treated diseases. Previous SV Funds have been diversified, multi-sector and multi-strategy private equity and venture capital funds.

Houman Ashrafian, Managing Partner in London in the Biotech Team said: “We are delighted to welcome Alex to the SV family. His deep expertise in venture and industry and science will be of enormous benefit to SV and more specifically the biotech team as we continue to identify cutting-edge therapeutic approaches in the precision medicine space.”

Alex Badamchi-Zadeh, said “I am thrilled to join SV and the investment team of the Impact Medicine Fund. SV is world-renowned for investing in the most innovative, scientifically driven, and transformative medicines, alongside creating world class teams to drive impactful treatments to patients. It is a privilege to work alongside Kate, Houman, Mike and the broader investment team whose track-record in identifying ground-breaking drugs is second-to-none.”

Alex joins SV from Xilio Therapeutics, a Kendall Square based biopharmaceutical company focused on developing highly-potent, tumor-targeted immune-oncology therapeutics. At Xilio Alex led Business Development and Strategy and helped to guide the company through their $100.5m Series B financing. Xilio Therapeutics is now an SV portfolio company following this financing. Prior to joining Xilio, Alex was a Member of the US Healthcare and Life Sciences Team at L.E.K. Consulting. In this role he advised investors and executives in the life sciences industry on corporate business unit, franchise and product strategic decisions.

Alex has a PhD in Medicine (Immunology) from Imperial College London and received his BA in Biological Sciences from the University of Oxford. Following completion of his PhD, Alex was a Postdoctoral Fellow at Harvard Medical School in Dr Dan H. Barouch’s lab, where he developed novel immunotherapies for cancers and HIV-1. He has authored over a dozen scientific publications (Nature, Science Immunology, Journal of Immunology), and was part of the team to develop the world’s first Zika virus vaccine in response to the 2016 epidemic.

About SV Health Investors

SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. SV invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.5B in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 175 companies with more than 75 of these having achieved successful acquisitions or IPOs.

Historically, SV managed funds have been diversified across the three sectors. However, the firm’s seventh vintage of core funds is separated into three distinct vehicles; the SV7 Impact Medicine Fund forms and funds early-stage biotechnology companies developing precision medicines, the Growth Fund accelerates growth-stage healthcare services, medical products and digital health companies and the Medtech Convergence Fund specialises in novel medical device and remote-monitoring technologies.

Alongside their core funds, SV manages the Dementia Discovery Fund, focused on discovering and developing novel therapeutics for dementia, and the International Biotechnology Trust plc, a publicly-traded investment trust.